Table 3.
ALL protocols currently used for Erwinia asparaginase (second- or third-line treatment)
| Protocol | Second-line treatment |
|---|---|
| NOPHO | Erwinia asparaginase 20 000 IU/m2 two–three-times/week (×6) |
| AIEOP | NB: Erwinia asparaginase as third-line |
| Erwinia asparaginase 20 000 IU/m2 every other day | |
| GMALL 07/2003 and 01/2003 | Erwinia asparaginase 20 000 IU/m2 three-times weekly (×5); IV (10 000 IU/m2 in patients older than 55 years) |
| COG | Erwinia asparaginase 25 000 IU/m2 three-times weekly (×6); IM |
| COALL-07-03 | Erwinia asparaginase 45 000 IU/m2 (×2) |
| Czech Republic | NB: Erwinia asparaginase as third-line |
| Induction and late intensification | |
| • Erwinia asparaginase 10 000 IU/m2 twice-weekly | |
| HR blocks | |
| • Erwinia asparaginase 10 000 IU/m2 twice-weekly | |
| First relapse | |
| • Erwinia asparaginase 10 000 IU/m2 twice-weekly | |
| DCOG ALL-10 | NB: Erwinia asparaginase as third-line |
| Induction | |
| • Erwinia asparaginase 10 000 IU/m2 two–three times/week | |
| Intensification (standard or medium risk) | |
| • Erwinia asparaginase 10 000 IU/m2 two–three times/week | |
| HR blocks | |
| Erwinia asparaginase 10 000 IU/m2, two–three times/week | |
| BFM-2000 | Protocol 1 |
| • Erwinia asparaginase 10 000 IU/m2 every 2 days IM/IV | |
| Protocol II | |
| • Erwinia asparaginase 10 000 IU/m2 every 2 days IM/IV | |
| Block HR-1 | |
| Erwinia asparaginase 10 000 IU/m2 every 2 days IM/IV | |
| EORTC-58951 | Erwinia asparaginase 20 000 IU/m2 two–three times/week; IM |
| FRALLE- 2000 | Induction, delayed intensification(s): Erwinia asparaginase 12 000 IU/m2 three times/week; IM, ie double dose compared to E.coli asparaginase |
| St Jude | Induction: |
| Erwinia asparaginase 20 000 IU/m2 three times/week (×6) IM; | |
| Post-remission: 30 000 or 42 000 IU/m2 twice-weekly IM for 30 weeks (standard-/high-risk patients), twice-weekly for 4 weeks during first and second reinduction (low-risk patients) | |
| DFCI ALL Consortium | Post-induction consolidation: |
| Erwinia Asparaginase 25 000 IU/m2 twice-weekly IM for 30 weeks |
NOPHO, Nordic Society of Pediatric Hematology and Oncology; AIEOP, Associazione Italiana Ematologia Oncologia Pediatrica; GMALL, German Multicenter Acute Lymphoblastic Leukemia Study Group; COG, Children's Oncology Group; COALL, Cooperative Study Group for Childhood Acute Lymphoblastic Leukemia; DCOG, Dutch Childhood Oncology Group; BFM, Berlin-Frankfurt-Münster; EORTC, European Organization for Research and Treatment of Cancer; FRALLE, French Acute Lymphobalstic Leukemia group; DFCI, Dana-Faber Cancer Institute; IV, intravenous; IM, intramuscular; HR, high risk